TTC14 inhibitors are a class of chemical compounds that specifically target and inhibit the TTC14 protein, which is a member of the tetratricopeptide repeat (TPR) domain-containing protein family. The TPR domains in TTC14 facilitate protein-protein interactions, often serving as scaffolding elements that stabilize or assemble protein complexes involved in various cellular functions. TTC14, in particular, plays a role in intracellular signaling and the regulation of protein complexes, influencing the dynamics of cellular processes. Inhibitors of TTC14 are designed to interfere with the protein's function by binding to its TPR domains or other critical regions, preventing it from engaging in its normal interactions with other proteins. By inhibiting TTC14, these compounds can alter specific molecular pathways in which TTC14 is a key participant.
The chemical structures of TTC14 inhibitors are typically engineered to achieve a high degree of specificity for the TTC14 protein, ensuring minimal off-target effects on other TPR-containing proteins. These inhibitors may contain molecular features such as aromatic rings, hydrogen bond donors, and hydrophobic groups that enhance their binding affinity to the TTC14 protein. The goal in designing TTC14 inhibitors is to effectively disrupt the protein's interaction network by blocking key binding sites. Researchers often study the structural and functional changes that occur in TTC14 upon inhibition, focusing on how these changes influence larger protein complexes and cellular pathways. By studying TTC14 inhibitors, scientists can gain valuable insights into the role of TTC14 in cellular regulation and the broader mechanisms of TPR domain-mediated protein assembly and interaction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] is a proteasome inhibitor that specifically inhibits the chymotrypsin-like activity of the proteasome, preventing the degradation of proteins. | ||||||
Reversine | 656820-32-5 | sc-203236 | 5 mg | $221.00 | 13 | |
Reversine is a small molecule inhibitor that disrupts the normal function of the APC/C complex by inhibiting Aurora kinases. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine inhibits cyclin-dependent kinases (CDKs), disrupting the normal function of the APC/C complex. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin inhibits the activity of the APC/C complex by disrupting its interaction with coactivators. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide disrupts the interaction between the APC/C complex and its coactivators, inhibiting its activity. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 inhibits Aurora kinases, disrupting the normal function of the APC/C complex. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $66.00 $163.00 $326.00 | 37 | |
RO-3306 is a selective inhibitor of CDK1, disrupting the normal function of the APC/C complex. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
MLN8237 inhibits Aurora kinases, disrupting the normal function of the APC/C complex. | ||||||
NSC 625987 | 141992-47-4 | sc-203653 | 10 mg | $159.00 | ||
NSC 625987 disrupts the interaction between the APC/C complex and its coactivators, inhibiting its activity. | ||||||